Genenta Science Spa Stock Investor Sentiment

GNTA Stock  USD 5.20  0.18  3.35%   
About 64% of Genenta Science's investor base is looking to short. The analysis of the overall investor sentiment regarding Genenta Science SpA suggests that many traders are alarmed. The current market sentiment, together with Genenta Science's historical and current headlines, can help investors time the market. In addition, many technical investors use Genenta Science SpA stock news signals to limit their universe of possible portfolio assets.
  

Genenta Science Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Genenta Science can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
Anixa Biosciences Announces Opening of Enrollment for Keytruda Arm in Ongoing Breast Cancer Vaccine ...
Google News at Macroaxis
over a year ago at news.google.com         
ADRs End Higher Missfresh Climbs 31.8 percent - Morningstar
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Yahoo News
over a year ago at news.google.com         
Kodiak stock cut to Neutral at UBS as lead asset dropped - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Kodiak stock falls discontinues eye disease candidate - Seeking Alpha
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Short Interest in Genenta Science S.p.A. Rises By 7.7
news
over a year ago at simplywall.st         
Were Hopeful That Genenta Science Will Use Its Cash Wisely
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
ADC Therapeutics discontinues Zynlonta study over safety concerns ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Vaxarts mid-stage trial for norovirus vaccine pill succeeds - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Cyteir stock surges on plans to wind down business - Seeking Alpha
Google News at Macroaxis
over a year ago at finance.yahoo.com         
The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma
Yahoo News
over a year ago at globenewswire.com         
The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
DermTech announces restructuring to focus on its Melanoma Test ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
JMP Securities Downgrades Adicet Bio to Market Perform From Market Outperform - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
TScan Therapeutics Shares Rise 17 percent After FDA Clears IND for Cancer Treatment - Marketscreener...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Genenta Science that are available to investors today. That information is available publicly through Genenta media outlets and privately through word of mouth or via Genenta internal channels. However, regardless of the origin, that massive amount of Genenta data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genenta Science news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genenta Science relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genenta Science's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genenta Science alpha.

Genenta Science Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
AlTi Global Inc. Acquires Shares of 200,288 Genenta Science S.p.A. - MarketBeat
09/26/2024
2
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
10/02/2024
3
Genenta Science S.p.A.s market cap rose US46m last week individual investors who hold 55 percent profited and so did insiders
10/11/2024
4
Genenta Science S.p.A. Quarterly 10-Q Report - Quartzy
11/12/2024
5
Genenta Science Shares Down 4.9 percent - Whats Next - MarketBeat
11/20/2024

Complementary Tools for Genenta Stock analysis

When running Genenta Science's price analysis, check to measure Genenta Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genenta Science is operating at the current time. Most of Genenta Science's value examination focuses on studying past and present price action to predict the probability of Genenta Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genenta Science's price. Additionally, you may evaluate how the addition of Genenta Science to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals